


WHAT WOULD SITE- NEUTRAL REFORM MEAN FOR CANCER PATIENTS?

Brian Connell
Vice President, Federal Affairs
LLS Office of Public Policy



A microscopic view of blood cells. The background is filled with numerous red blood cells, which are biconcave and appear as reddish-orange discs. In the lower right quadrant, a single white blood cell is prominently featured, appearing as a larger, irregularly shaped, light-colored cell with a textured surface. The overall lighting is dark, highlighting the individual cells against a deep red background.


**1.6 million
Americans**
are living with a
blood cancer
diagnosis

42%

of cancer patients
deplete their entire
life's assets two years
after diagnosis


Source: Gilligan et al (2018) American Journal of Medicine

51% HAVE INCURRED MEDICAL DEBT




Source: American Cancer Society Cancer Action Network (2022)
"Survivor Views: Cancer and Medical Debt"

Share of Total Medicare Outpatient Chemo Billed in Hospital Outpatient Setting



Source: MedPAC, June 2023 Report to Congress, Table 8-1

SHARE OF PHYSICIAN PRACTICES OWNED OR CONTROLLED BY HOSPITAL SYSTEMS (2007-2017)



Source: Nikpay et al (2018) Health Affairs, "Hospital-Physician Consolidation Accelerated in the Past Decade in Cardiology, Oncology"



MULTIPLE MYELOMA PATIENT

\$2,082 

out-of-pocket costs for treatment at a hospital

vs.

\$809 

out-of-pocket costs for treatment at a hospital

\$1,219 out-of-pocket annual savings

Source: Wakely (November 2023) "Site Neutral Payment Reform Has The Potential To Significantly Reduce Out-Of-Pocket Patient Spent"

2-YEAR PATIENT OUT-OF-POCKET COST IN MEDICARE – 24 MONTHS FOLLOWING A CANCER DIAGNOSIS, TOP DECILE

Diagnosis	OOP \$
Multiple Myeloma	\$47,253
Bone Marrow Disorder	\$40,279
Acute Leukemia	\$39,018
Lymphoma	\$36,075
Chronic Leukemia	\$29,984

*Among treated patients, newly diagnosed in 2015, in FFS

Source: Milliman, Inc. The cost burden of blood cancer care in Medicare. October 2019. Figure E1.



THANK YOU

The mission of The Leukemia & Lymphoma Society® (LLS) is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families.

We fund **RESEARCH** to advance lifesaving treatments

We drive **ADVOCACY** for policies that protect patient access to quality cancer care

We provide patients and families with hope, guidance, education and **SUPPORT**

